許恒，1976年生，籍貫山東，中國醫學科學院藥物研究所研究員，博士生導師，合成藥物化學室副主任。1998年本科畢業于南京大學化學系；2005年獲得美國德克薩斯大學阿靈頓分校博士學位； 2005-2008年在美國國立衛生研究院/國家癌癥研究所從事博士后研究；2008-2015年先后在葛蘭素史克中國研發中心和方正醫藥研究院從事新藥研發工作；2015年09月起擔任中國醫學科學院藥物研究所課題組長，主要進行小分子創新藥物的設計與研發。

抗腫瘤小分子藥物設計與研發；抗自身免疫性疾病小分子藥物設計與研發；基于蛋白靶向降解技術的藥物設計與研發；光控藥物設計與發現。

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Zhang, J.#; Jiang, H.#; Lin, S.#; Wu, D.; Tian, H.; Jiang, L.; Cui, Y.; Jin, J.*; Chen, X.*; Xu, H.* Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies. J. Med. Chem. 2022, 65, 8011-8028. (IF=8.039)

2. Ji, M.#; Wang, D.#; Lin, S., Wang, C.; Li, L.; Zhang, Z.; Jin, J.; Wu, D.; Dong, Y.; Xu, H.*; Lu, D.*; Chen, X.* A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma growth and brain metastasis in mice models. Acta Pharm. Sin. B 2022, 12, 774-786. (IF=14.911)

3. Dong, Y.#; Fu, R.#; Chen, J.; Zhang, K.; Ji, M.; Wang, M.; Jiang, H.; Ye, W.; Hu, J.; Li, Y.; Jin, J.*; Chen, X.*; Xu, H.* Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy. J. Med. Chem. 2021, 64, 16626-16640. (IF=8.039)

4. Zhang, K.#; Ji, M.#; Lin, S.; Peng, S.; Zhang, Z.; Zhang, M.; Zhang, J.; Zhang, Y.; Wu, D.; Tian, H.; Chen, X.*; Xu, H.* Design, Synthesis and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. J. Med. Chem. 2021, 64, 7331-7340. (IF=8.039)

5. Du, T.; Lin, S.; Ji, M.; Xue, N.; Liu, Y.; Zhang, Z.; Zhang, K.; Zhang, J.; Zhang, Y.; Wang, Q.; Sheng, L.; Li, Y.; Lu, D.*; Chen, X.*; Xu, H.* A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Lett. 2020, 495, 22-32. (IF=8.679)

6. Dong, Y.#; Chen, J.#; Cui, Y.; Bao, L.; Xu, H.* Cp*Rh^III-Catalyzed Sulfonamide Directed Ortho Arene C–H Carbenoid Functionalization with Pyridotriazoles. Org. Lett., 2020, 22, 772-775. (IF=6.222)

7. Dong, Y.#; Zhang, X.#; Chen, J.; Zou, W.; Lin, S.; Xu, H.* Switching the site-selectivity of C–H activation in aryl sulfonamides containing strongly coordinating N-heterocycles. Chem. Sci., 2019, 10, 8744-8751. (IF=9.346)

8. Lin, S.#; Jin, J.#; Liu, Y.#; Tian, H.; Zhang, Y.; Fu, R.; Zhang, J.; Wang, M.; Du, T.; Ji, M.; Wu, D.; Zhang, K.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery of 4-Methyl Quinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2019, 62, 8873-8879. (IF=6.205)

9.  Zhang, K.#; Lai, F.#; Lin, S.; Ji, M.; Zhang, J.; Zhang, Y.; Jin, J.; Fu, R.; Wu, D.; Tian, H.; Xue, N.; Sheng, L.; Zou, X.; Li, Y.; Chen, X.*; Xu, H.* Design, Synthesis and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. J. Med. Chem. 2019, 62, 6992-7014. (IF=6.205)

10. Lin, S.#; Wang, C.#; Ji, M.; Wu, D.; Lv, Y.; Zhang, K.; Dong, Y.; Jin, J.; Chen, J.; Zhang, J.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-kinase Inhibitors for Cancer Treatment. J. Med. Chem. 2018, 61, 6087–6109. (IF=6.054)